Esta traducción se está preparando. Mientras tanto, mostramos temporalmente la versión original en inglés.
Regulación de mercados · 7/11/19951 min de lectura
The Upjohn Company and Pharmacia Aktiebolag; Consent Agreement With Analysis to Aid Public Comment
Traducción automática local · Idioma original de la fuente
Resumen
In settlement of alleged violations of federal law prohibiting unfair acts and practices and unfair methods of competition, this consent agreement, accepted subject to final Commission approval, would require The Upjohn Company and Pharmacia Aktiebolag to divest Pharmacia's assets in ``9-AC,'' a topoisomerase I inhibitor drug for the treatment of colorectal cancer, to a Commission-approved buyer who will ensure that research and development will continue in competition with the merged company's product ``CPT-11,'' a topoisomerase I inhibitor drug developed by Upjohn.
Idioma original de la fuente: Federal Register — Federal Trade CommissionAbrir el comunicado original →